5 completed, 1 terminated, 1 unknown. 7 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Lenograstim: new trials by email Literature Review of Lenograstim trials Research Report on Lenograstim
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) Melphalan, Lenograstim - Castrate Resistant Prostate Cancer | Phase 2 / Phase 3 | Terminated | Barts & The London NHS Trust | 29 | 2013-01-01 | 2023-04-19 |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine Cytarabine, Idarubicin, Etoposide - Acute Myeloid Leukemia (AML) | Phase 2 | Completed | University of Ulm | 277 | 2010-11-01 | 2020-12-31 |
| Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy granulocyte colony stimulating factor (GCSF), bone marrow mononuclear cells - Dilated Cardiomyopathy | Phase 2 | Completed | Barts & The London NHS Trust | 60 | 2010-08-01 | 2013-11-15 |
| Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction Lenograstim (GRANOCYTE)=GCSF, Sitagliptin (Januvia), Sodium Chloride (NaCl) 0.9 % - Acute Myocardial Infarction | Phase 2 / Phase 3 | Completed | Ludwig-Maximilians - University of Munich | 174 | 2008-03-01 | 2022-08-25 |
| Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors filgrastim, lenograstim, pegfilgrastim - Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor | Phase 1 / Phase 2 | Unknown | University of Southampton | 23 | 2006-11-01 | 2013-01-23 |
| Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL Bortezomib, Cyclophosphamide, Doxorubicin - Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell | Phase 1 / Phase 2 | Completed | Asan Medical Center | 49 | 2006-09-01 | 2013-03-15 |
| Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy lenograstim - Hodgkin's Disease, Non-Hodgkin Lymphomas | Phase 2 / Phase 3 | Completed | WiSP Wissenschaftlicher Service Pharma GmbH | 169 | 2003-05-01 | 2010-03-11 |
Cardiomyopathy, Dilated (1) · Central Nervous System Neoplasms (1) · Endodermal Sinus Tumor (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Myocardial Infarction (1) · Ovarian Neoplasms (1) · Seminoma (1) · Testicular Germ Cell Tumor (1) · Testicular Neoplasms (1)
Barts & The London NHS Trust (2) · Asan Medical Center (1) · Ludwig-Maximilians - University of Munich (1) · University of Southampton (1) · University of Ulm (1) · WiSP Wissenschaftlicher Service Pharma GmbH (1)
United Kingdom (3) · Germany (2) · Austria (1) · South Korea (1)
Anthony Mathur, MD FRCP FESC (1) · Cheolwon Suh, M.D.,Ph.D. (1) · G. Mead, MD (1) · Jonathan Shamash, MD FRCP (1) · Richard F Schlenk, MD (1) · Wolfgang M Franz, Prof. Dr. (1)
PMID 21163927, PMID 26709136, PMID 37885041
2009 (1)